Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated January 18, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Not Yet Recruiting
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multicenter, single-arm trial will explore the efficacy and safety of liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer.
Trial Details
NCT Number NCT06192680
Lead Sponsor Harbin Medical University
Conditions
(from sponsor)		 Colorectal Cancer
Related terms Colorectal Neoplasms, Neoplasm Metastasis
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov